Cardiomyocytes derived from iPSCs offer a promising approach for cardiovascular disease modeling, drug screening, and regenerative medicine. Since adult cardiomyocytes are terminally differentiated and lack proliferative capacity, iPSC-derived cardiomyocytes provide a viable alternative for cell replacement therapy.